ASCO: Pemetrexed extends survival as maintenance therapy
Dr. Chandra P. Belani – Penn State Cancer Institute, Hershey, Pennsylvania, USA, speaking as ASCO press conference: ASCO press conference: A phase III study reports that maintenance therapy with pemetrexed (Alimta) improves overall survival in nonsquamous forms of advanced NSCLC.
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: extends, maintenance, therapy, asco, survival, pemetrexed
Lung Cancer News from ASCO 2010
Paul A. Bunn, Jr., MD (James Dudley Chair in Cancer Research,Professor and Director, University of Colorado Cancer Center) discusses the latest news in lung cancer at ASCO 2010.
Video Rating: 0 / 5
JVZoo Product Feed
ASCO History Minute with Dr. Emil Frei III on Combination Chemotherapy
Dr. Emil Frei III, 1968-1969 ASCO President, discusses the introduction of combination chemotherapy in cancer treatment. Learn more about ASCO’s history at www.asco.org.
JVZoo Product Feed
Categories: Videos Tags: combination, minute, emil, asco, chemotherapy, history, frei
ASCO 2009: Maintenance therapy for NSCLC
Dr. Vincent A. Miller – MD Memorial Sloan-Kettering Cancer Center, New York, USA ASCO press conference: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.
cancergrace.org Lecture on history and general approaches for radiation, with specific attention to its role in post-operative treatment of head/neck cancer, by Dr. Alex Lin, Assistant Professor of Radiation Oncology at the Univ. of Pennsylvania.
Video Rating: 0 / 5
JVZoo Product Feed
ASCO 2009: Oestrogen and progestin therapy increases NSCLC risk
ASCO 2009: Rowan T. Chlebowski, MD, PhD – Harbor-UCLA Medical Center – Los Angeles: Menopausal Hormone Therapy with Estrogen and Progestin Linked to Increased Risk of Death from Non-Small Cell Lung Cancer Researchers have shown that use of hormone therapy with estrogen plus progestin increases the risk of dying from non-small cell lung cancer (NSCLC) in women with the disease. Lung cancer is the leading cause of cancer death in US women.
JVZoo Product Feed
ASCO: Erbitux Gives Extra Time to Advanced Lung Cancer
www.medpagetoday.com David H. Johnson MD, Vanderbilt University CHICAGO — For advanced non-small-cell lung cancer, cetuximab (Erbitux) added to platinum-based chemotherapy increased median survival by five weeks, according to an international study.
Video Rating: 5 / 5
“Tomorrow’s Technology to Treat Cancer Today” Tumors within the body all move during treatment. Cyberknife VSI is the only technology in the world that detects, tracks and treats tumors in motion with SUB-MILLIMETER accuracy. Cyberknife VSI treatments are completed in 5 consecutive days, each treatment lasting 20-45 minutes. At Phoenix Cyberknife and Radiation Oncology Center we offer patients the 3 most advanced Radiation Technologies in one center. This is the first center in the world offering you the Novalis Truebeam STx, Cyberknife VSI and Multi-source HDR Brachytherapy. Cancerous and non-Cancerous tumors come in all shapes, sizes and locations throughout the body. John J Kresl, MD, PhD, FACRO, Medical Director and his team at ROCA, give you over 50 years of combined experience, to treat your unique condition with the optimal technology, with a friendly supportive staff. Call us for a consult : 602-441-3845 www.phoenixcyberknife.com
JVZoo Product Feed
ASCO: Genes Guide Early Stage NSCLC Treatment Decisions
www.medpagetoday.com Ming Tsao, MD, University of Toronto CHICAGO — A genetic test may help determine which early stage non-small-cell lung cancer patients can be spared chemotherapy after surgery, researchers said here.
Video Rating: 5 / 5
JVZoo Product Feed
ASCO 2009: Experimental targeted therapy improves progression-free survival for advanced NSCLC
Dr Roy Herbst, MD Anderson Cancer Center, Houston, US ASCO 2009: Experimental Targeted Therapy Vandetanib Improves Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer The results of an international trial have shown that adding the experimental targeted therapy vandetanib (Zactima) to docetaxel improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after first-line treatment. This is the first phase III study to show that adding a targeted therapy to second-line chemotherapy with docetaxel results in a clinical benefit for patients with advanced.
JVZoo Product Feed
Categories: Videos Tags: nsclc, survival, improves, experimental, asco, therapy, 2009, advanced, targeted, progressionfree
ASCO 2010: ALK mutation related non-small cell lung cancer
Prof George Demetri – Harvard Medical School, USA Prof Demetri describes two key presentations from ASCO 2010: the rapid progress made developing a therapy for ALK mutation related non-small cell lung cancer patients and the encouraging results of a phase I study into inflammatory myofibroblastic tumour patients with the ALK mutation. Prof Demitri goes on to discuss his current research into the Hsp90 pathway, kinase inhibitors, cancer profiling and IGF-1 receptor agonists.
Video Rating: 0 / 5
JVZoo Product Feed
ASCO 2009: Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo
Pierre Fouret, MD, PhD, Institut Gustave Roussy, Université Pierre et Marie Curie, Paris, France: Speaking at ASCO 2009: Lung Cancer Patients Lacking MSH2 DNA Repair Protein Fare Better with Chemotherapy: An analysis from the International Adjuvant Lung Trial (IALT) reports that tumor levels of the MSH2 protein predict long-term response to cisplatin-based chemotherapy among patients with surgically removed non-small cell lung cancer (NSCLC). MSH2 is a protein that cancer cells use to repair DNA damaged by cisplatin. Researchers found that patients with no or low levels of the MSH2 protein respond better to treatment than patients with high levels.
Video Rating: 0 / 5
JVZoo Product Feed
Ronald H. Blum, MD: Lung Cancer Update ASCO 2011
Dr. Ronald Blum gives a lung cancer update at ASCO 2011. Ronald H. Blum, MD is the Director, Cancer Centers and Programs, Beth Israel and St. Luke’s-Roosevelt.
Video Rating: 0 / 5
Lung cancer expert Gregory Otterson, MD, of Ohio State University Comprehensive Cancer Center, describes promising areas of research in lung cancer—especially lung cancer screening—in this video from the National Comprehensive Cancer Network (NCCN). The NCCN is a not-for-profit alliance of 21 leading cancer centers— including Ohio State University Comprehensive Cancer Center —dedicated to improving cancer care for all patients. You can find more information on lung cancer, including diagnosis and treatment options, at www.NCCN.com.
JVZoo Product Feed
ASCO 2010: Clinical Trials and Advanced Non-small Cell Lung Cancer
Dr. Michael Boyer, Head of Medical Oncology at Sydney Cancer Center, discusses data for PF299804.
JVZoo Product Feed
ASCO 2010: Phase III clinical trials at ASCO 2010
Prof Patrick Schöffski – Catholic University Leuven, Belgium Prof Schöffski talks about two phase III trial results presented at ASCO 2010. The first of these demonstrated that the tyrosine kinase inhibitor vandetanib increases progression free survival in patients with advanced metastatic medullary thyroid carcinoma and the second found that a combination of platinum salt and paclitaxel is an effective and inexpensive treatment for elderly patients with non-small cell lung cancer. Prof Schöffski goes on to outline a phase II study his group is currently working on, looking at eribulin as a treatment for patients with advanced metastatic sarcomas.
JVZoo Product Feed
Lung Cancer News from the 2011 ASCO Annual Meeting
Dr. Mark Kris discusses the news highlighted at ASCO’s 2011 Annual Meeting that covers research on managing cancer as a chronic disease, and includes information on lung cancer. For more information, visit Cancer.Net (www.cancer.net).
JVZoo Product Feed
ASCO 2010: ALK Gene, Exciting News for Some Lung Cancer Patients
Bruce Johnson, MD discusses the exciting new ALK gene clinical trial data benefiting a subset of lung cancer patients.
Video Rating: 0 / 5
JVZoo Product Feed
Data from Pre-Clinical Studies Presented at the 2011 ASCO Annual Meeting Show Potential Combinability of Custirsen …
Cops for Cancer- Title Sponsor Coast Capital Savings (22)
Image by Ron Sombilon Gallery
Coast Capital Savings Proudly Sponsors COPS FOR CANCER.
Help us help the kids.
We are proud to be the official Tour Sponsor of the 2009 Canadian Cancer Society Cops for Cancer tour, a partnership between the Canadian Cancer Society and local police agencies to raise funds for research into paediatric cancer research, programs and camps like Camp Goodtimes.
When does the campaign start?
We’re excited to kick off our annual fundraising campaign for this important cause on Wednesday, August 19. The campaign will run until Saturday, October 3. Keep your eyes peeled for more information at a branch near you this August.
Thanks in part to the generosity of our staff and members, hundreds of BC children living with cancer had the opportunity to attend Camp Goodtimes last year. For these children, Camp Goodtimes is a special place, providing them with the opportunity to just be kids and to be around other children with cancer.
The Canadian Cancer Society Cops for Cancer tour is our largest corporate fundraiser and to date weâve raised a whopping .5 million for this cause. In 2008, our staff raised more than 8,000 through fundraisers such as head shaves, karaoke contests, bake sales, and more.
Find more information on the Cops for Cancer tour here:
Tour de Valley: Fraser Valley
Tour de Coast: Greater Vancouver
Tour de Rock: Vancouver Island
For more info visit
www.coastcapitalsavings.com/About_Coast_Capital_Savings/H…
Data from Pre-Clinical Studies Presented at the 2011 ASCO Annual Meeting Show Potential Combinability of Custirsen …
OncoGenex Pharmaceuticals, Inc. announced new data showing how the company’s lead investigational compound, custirsen , may work with innovative therapies MDV3100 and heat-shock protein 90 inhibitors to suppress prostate cancer cell survival and improve treatment outcomes.
Read more on PR Newswire via Yahoo! Finance
Synta Announces Presentation of Additional Ganetespib Results at ASCO
Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.
Read more on Business Wire via Yahoo! Finance
JVZoo Product Feed
Categories: News Tags: preclinical, studies, combinability, show, data, meeting, from, custirsen, 2011, annual
Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
Cops for Cancer- Title Sponsor Coast Capital Savings (28)
Image by Ron Sombilon Gallery
Coast Capital Savings Proudly Sponsors COPS FOR CANCER.
Help us help the kids.
We are proud to be the official Tour Sponsor of the 2009 Canadian Cancer Society Cops for Cancer tour, a partnership between the Canadian Cancer Society and local police agencies to raise funds for research into paediatric cancer research, programs and camps like Camp Goodtimes.
When does the campaign start?
We’re excited to kick off our annual fundraising campaign for this important cause on Wednesday, August 19. The campaign will run until Saturday, October 3. Keep your eyes peeled for more information at a branch near you this August.
Thanks in part to the generosity of our staff and members, hundreds of BC children living with cancer had the opportunity to attend Camp Goodtimes last year. For these children, Camp Goodtimes is a special place, providing them with the opportunity to just be kids and to be around other children with cancer.
The Canadian Cancer Society Cops for Cancer tour is our largest corporate fundraiser and to date weâve raised a whopping .5 million for this cause. In 2008, our staff raised more than 8,000 through fundraisers such as head shaves, karaoke contests, bake sales, and more.
Find more information on the Cops for Cancer tour here:
Tour de Valley: Fraser Valley
Tour de Coast: Greater Vancouver
Tour de Rock: Vancouver Island
For more info visit
www.coastcapitalsavings.com/About_Coast_Capital_Savings/H…
Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma .
Read more on Business Wire via Yahoo! Finance
JVZoo Product Feed
Categories: News Tags: millenium et sgn 35, asco brentuximab, sgn-35 asco, updated, genetics, asco sgn-35, data, sgn-35 millenium, seattle, brentuximab millenium
A decade dedicated to breast cancer care advocacy garners ASCO Award for researcher
A decade dedicated to breast cancer care advocacy garners ASCO Award for researcher
( Fred Hutchinson Cancer Research Center ) Benjamin Anderson, M.D., a researcher in the Public Health Sciences Division of Fred Hutchinson Cancer Research Center and director of Seattle Cancer Care Alliance’s Breast Health Clinic, is the 2011 recipient of the Partners in Progress award given by the American Society of Clinical Oncology.
Read more on EurekAlert!
Study finds bankruptcy rates among cancer patients increase along with survival time
( Fred Hutchinson Cancer Research Center ) An analysis linking federal bankruptcy court records to cancer registry data from nearly 232,000 adult cancer cases in western Washington during a 14-year period has found a hidden cost to survival: Insolvency rates increase along with the length of survival.
Read more on EurekAlert!
JVZoo Product Feed
Categories: News Tags: care, dedicated, cancer, breast, award, researcher, advocacy, asco, garners, decade
Women’s Cancers News from the 2011 ASCO Annual Meeting
Dr. Andrew Seidman talks about some of the advances in breast and ovarian cancers coming out of the 2011 ASCO Annual Meeting. For more information, visit Cancer.Net (www.cancer.net).
Video Rating: 0 / 5
JVZoo Product Feed
Cylene Presents Encouraging Clinical Data for Oral CK2 Inhibitor at ASCO
Cylene Presents Encouraging Clinical Data for Oral CK2 Inhibitor at ASCO
Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology annual meeting held on June 4-8 in Chicago, IL.
Read more on PR Newswire via Yahoo! Finance
Veterans Health Administration similar or better than private sector for cancer patients ages 65+
( Harvard Medical School ) Cancer care provided by the Veterans Health Administration for men 65 years and older is at least as good as, and by some measures better than, Medicare-funded fee-for-service care obtained through the private sector.
Read more on EurekAlert!
JVZoo Product Feed
